Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TARA

TARA - ArTara Therapeutics Inc Stock Price, Fair Value and News

$7.19-0.08 (-1.10%)
Market Closed

Price Targets

TARA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TARA Price Action

Last 7 days

24.6%

Last 30 days

34.1%

Last 90 days

39.9%

Trailing 12 Months

59.1%

TARA RSI Chart

TARA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TARA Valuation

Market Cap

277.4M

Price/Earnings (Trailing)

-5.24

Price/Sales (Trailing)

667.18

Price/Free Cashflow

-5.69

TARA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

TARA Fundamentals

TARA Revenue

Revenue (TTM)

262.0K

TARA Earnings

Earnings (TTM)

-52.9M

Earnings Growth (Yr)

-18.17%

Earnings Growth (Qtr)

11.38%

TARA Profitability

Return on Equity

-39.99%

Return on Assets

-36.58%

Free Cashflow Yield

-17.59%

TARA Investor Care

Shares Dilution (1Y)

87.05%

Diluted EPS (TTM)

-1.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2019449.0K416.0K356.0K262.0K
2018319.0K379.0K409.0K436.0K
2017169.0K162.0K199.0K259.0K
2016160.0K176.0K188.0K193.0K
20152.2M1.5M845.0K144.0K
20140002.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About ArTara Therapeutics Inc

TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.
 CEO
 WEBSITEprotaratx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES25

ArTara Therapeutics Inc Frequently Asked Questions

TARA is the stock ticker symbol of ArTara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ArTara Therapeutics Inc is 277.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TARA's fair value in chart for subscribers.

The fair value guage provides a quick view whether TARA is over valued or under valued. Whether ArTara Therapeutics Inc is cheap or expensive depends on the assumptions which impact ArTara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TARA.

As of Wed Jan 28 2026, TARA's PE ratio (Price to Earnings) is -5.24 and Price to Sales (PS) ratio is 667.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TARA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ArTara Therapeutics Inc has provided -0.326 (multiply by 100 for percentage) rate of return.